<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02516501</url>
  </required_header>
  <id_info>
    <org_study_id>15025</org_study_id>
    <nct_id>NCT02516501</nct_id>
  </id_info>
  <brief_title>Impact of a Ketogenic Diet Intervention During Radiotherapy on Body Composition</brief_title>
  <acronym>KETOCOMP</acronym>
  <official_title>Investigating the Impact of a Ketogenic Diet Intervention During Radiotherapy on Body Composition: A Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MVZ Leopoldina GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MVZ Leopoldina GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type of study: Pilot / phase I trial&#xD;
&#xD;
      Study purpose To assess the impact of a dietary intervention during radio(chemo)therapy (RCT)&#xD;
      on body composition changes&#xD;
&#xD;
      Trial Treatment Patients will be split into a control group and intervention group 1. If&#xD;
      willing to undertake a ketogenic diet for the duration of radiotherapy, patients are entered&#xD;
      into intervention group 2.&#xD;
&#xD;
        -  Group 1: On irradiation days irradiation after overnight fast + ketogenic breakfast&#xD;
           consisting of 50-250 ml betaquik® (vitaflo, Bad Homburg, Germany) and 10g MyAmino (dr.&#xD;
           reinwald healthcare gmbh + co kg, Altdorf, Germany).&#xD;
&#xD;
        -  Group 2: Complete ketogenic diet plus 10g MyAmino/day&#xD;
&#xD;
        -  Control: No dietary intervention.&#xD;
&#xD;
        -  All groups: Weight measurements and bioimpedance analysis (BIA) once per week, routine&#xD;
           blood parameters and quality of life (QoL) questionnaire before, during and after RCT&#xD;
&#xD;
      Endpoints&#xD;
&#xD;
      Primary:&#xD;
&#xD;
        -  Feasibility of the dietary intervention during RCT, measured by dropout rates&#xD;
&#xD;
        -  Changes in body weight&#xD;
&#xD;
        -  BIA phase angle and quantities derived from BIA variables&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  QoL&#xD;
&#xD;
        -  Toxicities&#xD;
&#xD;
        -  Blood parameters&#xD;
&#xD;
        -  Grade of regression at time of surgery in case of rectum carcinomas&#xD;
&#xD;
      Inclusion criteria&#xD;
&#xD;
        -  One of the following tumor entities:&#xD;
&#xD;
             -  Breast carcinoma&#xD;
&#xD;
             -  Rectum carcinoma&#xD;
&#xD;
             -  Head &amp; Neck Cancer&#xD;
&#xD;
        -  Histological confirmation of malignancy&#xD;
&#xD;
        -  Signed written informed consent&#xD;
&#xD;
        -  Karnofsky index ≥ 70&#xD;
&#xD;
        -  Age between 18 and 75 years&#xD;
&#xD;
        -  BMI between 18 and 34 kg/m^2&#xD;
&#xD;
      Exclusion criteria&#xD;
&#xD;
        -  Palliative patients, in particular with metastasis&#xD;
&#xD;
        -  Type I diabetes&#xD;
&#xD;
        -  Pregnancy&#xD;
&#xD;
        -  Pacemaker and other metallic parts within the body&#xD;
&#xD;
        -  Known defects in enzymes necessary for ketogenesis, ketolysis, fatty acid oxidation or&#xD;
           gluconeogenesis&#xD;
&#xD;
        -  Unable to speak or understand German&#xD;
&#xD;
        -  Cognitive impairments or psychological disorders&#xD;
&#xD;
        -  Renal insufficiency&#xD;
&#xD;
      Planned accrual&#xD;
&#xD;
        -  15 patients with colorectal and mammary tumor plus 5 patients with H&amp;N cancer in&#xD;
           intervention group 1&#xD;
&#xD;
        -  15 patients with colorectal and mammary tumor plus 5 patients with H&amp;N cancer in control&#xD;
           group&#xD;
&#xD;
        -  Minimum 5 patients of each tumor entity in intervantion group 2 Total: n ≥ 85 patients&#xD;
&#xD;
      Study procedure&#xD;
&#xD;
        1. Inclusion and full written informed consent.&#xD;
&#xD;
        2. Baseline BIA measurement and blood work&#xD;
&#xD;
        3. RCT with weekly BIA assessments; at least one blood withdrawal ± concurrent dietary&#xD;
           intervention&#xD;
&#xD;
        4. Final BIA measurement and blood work after radiotherapy&#xD;
&#xD;
      Follow up For rectal carcinoma: Regression at time of surgery (c and p)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">October 2021</completion_date>
  <primary_completion_date type="Actual">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dropout rate</measure>
    <time_frame>5-6 weeks</time_frame>
    <description>Dropout rates (intervention groups 1+2) to assess feasibility/tolerability of the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body composition</measure>
    <time_frame>5-6 weeks</time_frame>
    <description>This is a composite measure of several parameters obtained from the bioimpedance scale (mBCA 515, seca Germany). Body weight and composition derived from bioimpedance analysis will be assessed at least once per week. Body composition is composed of fat mass, fat free mass, total body water, extracellular water and intracellular water.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase angle</measure>
    <time_frame>5-6 weeks</time_frame>
    <description>The phase angle is a raw parameter of bioimpedance analysis and will be tracked weekly at a total of 19 frequencies (1, 1.5,2,3,5,7.5,10,15,20,30,50,75,100,150,200,300,500,1000 kHz). The Focus will be on the Phase angle at 50kHz which is a standard frequency of most BIA devices.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5-6 weeks</time_frame>
    <description>Evaluation of quality of life using EORTC QLQ-C30 and site-specific questionnaires at start, in the middle and at the end of RT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood parameters</measure>
    <time_frame>Blood parameters will be determined up to one week before the first RT fraction, at least once during their RT course (after an expected 3 weeks) and during their last week of RT..</time_frame>
    <description>This is a composite measure of relevant blood parameters including small blood count, glucose, albumin, urea, HbA1c, beta-hydroxybutyrate, triglycerides, HDl and LDL cholesterol, creatinine, liver enzymes, insulin, IGF-1, TSH, free T3 and T4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regression grade (TNM classification)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Only for colorectal carcinoma patients undergoing neoadjuvant RT: cTN status prior to and ypTN status after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normal tissue toxicity after RT</measure>
    <time_frame>5-6 weeks</time_frame>
    <description>Toxicity related to RT evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group that will not receive advice to follow a ketogenic diet or reduce carbohydrates.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who will receive each radiotherapy (RT) fraction after an overnight fast and subsequently ingest a ketogenic breakfast consisting of (i) up to 250 ml of a medium chain triglyceride drink (betaquik, vitaflo) plus (ii) 10g amino acids (MyAmino, dr. reinwald gmbh + co kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who will follow a ketogenic diet throughout the whole period of RT, Patients don't have to fast prior to each RT fraction, but will receive MyAmino analogous to Intervention group 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MyAmino</intervention_name>
    <description>MyAmino is a supplement containing the eight essential amino acids. MyAmino has a theoretical net nitrogen utilization of 99%, so that almost no glucose will be created out of the maino acids.</description>
    <arm_group_label>Intervention group 1</arm_group_label>
    <arm_group_label>Intervention group 2</arm_group_label>
    <other_name>Master amino acid pattern (MAP)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>betaquik</intervention_name>
    <description>betaquik is a medium chain triglyceride (MCT) emulsion. One bottle is 225ml corresponding to 45g MCT fats.</description>
    <arm_group_label>Intervention group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radio(chemo)therapy</intervention_name>
    <description>Radio(chemo)therapy as recommended by the institutional interdisciplinary tumor board.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Intervention group 1</arm_group_label>
    <arm_group_label>Intervention group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  RT of one of the following tumor entities: Mammary carcinoma, colorectal carcinoma,&#xD;
             head and neck carcinoma&#xD;
&#xD;
          -  Histologicallý confirmed malignant Tumor&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Karnofsky index &gt;= 70&#xD;
&#xD;
          -  18 kg/m^2 &lt; BMI &lt; 34 kg/m^2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Palliative Treatment&#xD;
&#xD;
          -  Type I Diabetes&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Pacemaker and othe rmetallic parts that make BIA predictions unreliable&#xD;
&#xD;
          -  Unable to understand and speak German&#xD;
&#xD;
          -  Cognitive impairments&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  intake of carboanhydrase-inhibitors&#xD;
&#xD;
          -  Rare metabolic disorders that speak against a ketogenic diet&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer J Klement, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, Leopoldina Hospital Schweinfurt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Radiotherapy and Radiation Oncology</name>
      <address>
        <city>Schweinfurt</city>
        <state>Bavaria</state>
        <zip>97421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Klement RJ, Sweeney RA. Impact of a ketogenic diet intervention during radiotherapy on body composition: I. Initial clinical experience with six prospectively studied patients. BMC Res Notes. 2016 Mar 5;9:143. doi: 10.1186/s13104-016-1959-9.</citation>
    <PMID>26946138</PMID>
  </reference>
  <reference>
    <citation>Klement RJ, Schäfer G, Sweeney RA. A fatal case of Fournier's gangrene during neoadjuvant radiotherapy for rectal cancer. Strahlenther Onkol. 2019 May;195(5):441-446. doi: 10.1007/s00066-018-1401-4. Epub 2018 Nov 23.</citation>
    <PMID>30470845</PMID>
  </reference>
  <reference>
    <citation>Klement RJ, Sweeney RA. Impact of a ketogenic diet intervention during radiotherapy on body composition: II. Protocol of a randomised phase I study (KETOCOMP). Clin Nutr ESPEN. 2016 Apr;12:e1-e6. doi: 10.1016/j.clnesp.2015.11.001. Epub 2016 Jan 15.</citation>
    <PMID>28531663</PMID>
  </reference>
  <results_reference>
    <citation>Klement RJ, Schäfer G, Sweeney RA. A ketogenic diet exerts beneficial effects on body composition of cancer patients during radiotherapy: An interim analysis of the KETOCOMP study. J Tradit Complement Med. 2019 Mar 21;10(3):180-187. doi: 10.1016/j.jtcme.2019.03.007. eCollection 2020 May.</citation>
    <PMID>32670812</PMID>
  </results_reference>
  <results_reference>
    <citation>Klement RJ, Champ CE, Kämmerer U, Koebrunner PS, Krage K, Schäfer G, Weigel M, Sweeney RA. Impact of a ketogenic diet intervention during radiotherapy on body composition: III-final results of the KETOCOMP study for breast cancer patients. Breast Cancer Res. 2020 Aug 20;22(1):94. doi: 10.1186/s13058-020-01331-5.</citation>
    <PMID>32819413</PMID>
  </results_reference>
  <results_reference>
    <citation>Klement RJ, Weigel MM, Sweeney RA. A ketogenic diet consumed during radiotherapy improves several aspects of quality of life and metabolic health in women with breast cancer. Clin Nutr. 2021 Jun;40(6):4267-4274. doi: 10.1016/j.clnu.2021.01.023. Epub 2021 Jan 27.</citation>
    <PMID>33551218</PMID>
  </results_reference>
  <results_reference>
    <citation>Klement RJ, Koebrunner PS, Meyer D, Kanzler S, Sweeney RA. Impact of a ketogenic diet intervention during radiotherapy on body composition: IV. Final results of the KETOCOMP study for rectal cancer patients. Clin Nutr. 2021 Jul;40(7):4674-4684. doi: 10.1016/j.clnu.2021.05.015. Epub 2021 May 31.</citation>
    <PMID>34233255</PMID>
  </results_reference>
  <results_reference>
    <citation>Klement RJ, Meyer D, Kanzler S, Sweeney RA. Ketogenic diets consumed during radio-chemotherapy have beneficial effects on quality of life and metabolic health in patients with rectal cancer. Eur J Nutr. 2021 Jun 27. doi: 10.1007/s00394-021-02615-y. [Epub ahead of print]</citation>
    <PMID>34175978</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 31, 2015</study_first_submitted>
  <study_first_submitted_qc>August 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2015</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ketogenic Diet</keyword>
  <keyword>Body composition</keyword>
  <keyword>Radiation therapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

